Advertisement


Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies

2017 ASCO Annual Meeting

Advertisement

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous vs matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure. (Abstracts 7506, 7508)



Related Videos

Neuroendocrine Tumors

Greta Stifel on Neuroendocrine Tumors: A Patient's Message to Physicians 

Greta Stifel recounts her story about a misdiagnosed tumor and urges physicians to raise awareness of neuroendocrine disease.

Bruce E. Johnson, MD, and Julie Vose, MD, MBA: A Conversation With ASCO’s 2017–2018 President

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, and Bruce E. Johnson, MD, of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, discuss Dr. Johnson’s upcoming tenure as ASCO President and his goals for the year ahead.

Issues in Oncology

Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates

Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)

Issues in Oncology

Solange Peters, MD, PhD, and Mary Gospodarowicz, MD, on Mentoring Women in Oncology: An International Perspective

Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD, of Princess Margaret Hospital, a recipient of the 2017 Women Who Conquer Cancer Mentorship Award.

Colorectal Cancer

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Advertisement

Advertisement




Advertisement